An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer
Ann Transl Med
.
2019 Mar;7(Suppl 1):S53.
doi: 10.21037/atm.2019.03.09.
Authors
Muhammad Zubair Afzal
1
,
Konstantin H Dragnev
2
,
Keisuke Shirai
2
Affiliations
1
Hospital Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
2
Department of Hematology-Oncology, One Medical Center Dr., Lebanon, NH, USA.
PMID:
31032332
PMCID:
PMC6462590
DOI:
10.21037/atm.2019.03.09
No abstract available
Publication types
Editorial
Comment